Acorda Therapeutics, Inc.

1.0700 15.3962
52 weeks
52 weeks

Mkt Cap 69.31M

Shares Out 48.13M

Send me real-time posts from this site at my email

Spark Therapeutics ONCE shares rise 8% on unconfirmed FTC report

Price and Volume Movers

Anika Therapeutics, Inc. (NASDAQ: ANIK) shares are trading up 11% after hours to $60.25 on the back of reporting better than expected 3Q earnings. Total revenue for the quarter increased 11% year-over-year to $29.7m.

Spark Therapeutics Inc (NASDAQ: ONCE) shares spiked in late trading to close the session up 8% to $108.64. Capitol Forum reported that Federal Trade Commission staff has approved the acquisition by Roche of Spark. The report has not been confirmed by the respective companies.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) shares closed up 42% to $0.31 on news that interim data from its Phase 3 trial of Iomab-B, in patients with Acute Myeloid Leukemia, will be announced during a conference call on Monday October 28 at 12noon ET.

Melinta Therapeutics, Inc. (NASDAQ: MLNT) announced the FDA has approved Baxdela (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria. Shares are trading down 27% to $3.18 after hours.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that its second Phase 3 trial THWART-1 (WART-301), of A-101 45% Topical Solution (A-101 45%), for the treatment of common warts, met the primary and all secondary efficacy endpoints, achieving clinically meaningful and statistically significant clearance of common warts. Shares are trading after hours up 18% to $1.99.

PDS Biotechnology Corporation (NASDAQ: PDSB) shares closed up 15% to $3.68. Coverage was initiated by Chardan with a Buy rating and a price target of $10.

Allergan plc (NYSE:AGN) announced that the FDA approved its supplemental Biologics License Application (sBLA) for Botox for the treatment of pediatric patients with lower limb spasticity.

BeyondSpring Inc. (NASDAQ:BYSI) shares are trading down 16% after hours following its announcement of an underwritten public offering of its shares.

Acorda Therapeutics, Inc. (NASDAQ: ACOR) shares closed down 26% to $2.00. The company announced Wednesday it will reduce its headcount by 25%, while JP Morgan today downgraded its rating of the company from Neutral to Underweight.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume


TrovaGene, Inc. (TROV): $2.24; +32%.

Rigel Pharmaceuticals, Inc. (RIGL): $2.05; +17%.

Sesen Bio, Inc. (SESN): $1.38; +16%.

Aptose Biosciences Inc. (APTO): $2.10; +15%.

Nymox Pharmaceutical Corporation (NYMX): $2.17; +10%.


TherapeuticsMD, Inc. (TXMD): $2.87; -22%.

Equillium, Inc. (EQ): $3.00; -15%.

OPKO Health, Inc. (OPK): $1.63; -14%.

Diffusion Pharmaceuticals Inc. (DFFN): $1.17; -10%.

AMAG Pharmaceuticals, Inc. (AMAG): $10.77; -9%.

Pipeline updates below:

Pipeline Database Updates


Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue